Literature DB >> 3377382

Reduced cyclic myopia with pilocarpine gel.

A I Mandell1, L A Bruce, M A Khalifa.   

Abstract

Pilocarpine 4% gel and pilocarpine 4% solution were compared in young normal subjects for their effects on induced myopia. The pilocarpine 4% solution produced marked myopia lasting one to two hours which indicates that a qid therapeutic regimen produces about three to six hours of blurred vision during waking hours. The gel-induced myopic effects returned to normal in most subjects nine hours after a single instillation. Thus, pilocarpine-gel-induced myopic effects occur principally while asleep and are reduced substantially upon awakening. This allows patients to carry on normal activities throughout the day.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3377382

Source DB:  PubMed          Journal:  Ann Ophthalmol        ISSN: 0003-4886


  6 in total

1.  Efficacy and safety of the combination therapy Pilogel/beta-blocker: interim results.

Authors:  S Maas; F E Ros; L J De Heer; R J De Keizer
Journal:  Doc Ophthalmol       Date:  1989-08       Impact factor: 2.379

2.  Long-term treatment with Pilogel/beta-blocker in glaucoma patients.

Authors:  S Maas; F E Ros; L J De Heer; R J De Keizer
Journal:  Int Ophthalmol       Date:  1991-07       Impact factor: 2.031

Review 3.  New developments in the drug treatment of glaucoma.

Authors:  L M Hurvitz; P L Kaufman; A L Robin; R N Weinreb; K Crawford; B Shaw
Journal:  Drugs       Date:  1991-04       Impact factor: 9.546

Review 4.  ATP sensitive potassium channel openers: A new class of ocular hypotensive agents.

Authors:  Uttio Roy Chowdhury; Peter I Dosa; Michael P Fautsch
Journal:  Exp Eye Res       Date:  2016-04-26       Impact factor: 3.467

5.  Pharmacological Profile and Ocular Hypotensive Effects of Cromakalim Prodrug 1, a Novel ATP-Sensitive Potassium Channel Opener, in Normotensive Dogs and Nonhuman Primates.

Authors:  Uttio Roy Chowdhury; Rachel A Kudgus; Bradley H Holman; Tommy A Rinkoski; Cheryl R Hann; Cindy K Bahler; Eric McCloud; Susan E Appt; Joel M Reid; Peter I Dosa; Michael P Fautsch
Journal:  J Ocul Pharmacol Ther       Date:  2021-03-30       Impact factor: 2.850

6.  Ocular Hypotensive Effects of the ATP-Sensitive Potassium Channel Opener Cromakalim in Human and Murine Experimental Model Systems.

Authors:  Uttio Roy Chowdhury; Cindy K Bahler; Bradley H Holman; Peter I Dosa; Michael P Fautsch
Journal:  PLoS One       Date:  2015-11-04       Impact factor: 3.240

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.